Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States

We assessed the frequency and severity of adverse events (AEs) in 53 patients with Chagas disease treated with nifurtimox in a US clinic. There were 435 AEs, but 93.8% were mild. Moderate/severe AEs were associated with premature treatment cessation.

Bibliographic Details
Main Authors:	Forsyth, Colin J., Hernandez, Salvador, Olmedo, Wilman, Abuhamidah, Adieb, Traina, Mahmoud I., Sanchez, Daniel R., Soverow, Jonathan, Meymandi, Sheba K.
Format:	Online
Language:	English
Published:	Oxford University Press 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036918/

id	pubmed-5036918
recordtype	oai_dc
spelling	pubmed-50369182016-09-27 Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States Forsyth, Colin J. Hernandez, Salvador Olmedo, Wilman Abuhamidah, Adieb Traina, Mahmoud I. Sanchez, Daniel R. Soverow, Jonathan Meymandi, Sheba K. Articles and Commentaries We assessed the frequency and severity of adverse events (AEs) in 53 patients with Chagas disease treated with nifurtimox in a US clinic. There were 435 AEs, but 93.8% were mild. Moderate/severe AEs were associated with premature treatment cessation. Oxford University Press 2016-10-15 2016-07-17 /pmc/articles/PMC5036918/ /pubmed/27432838 http://dx.doi.org/10.1093/cid/ciw477 Text en © The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, contact journals.permissions@oup.com.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Forsyth, Colin J. Hernandez, Salvador Olmedo, Wilman Abuhamidah, Adieb Traina, Mahmoud I. Sanchez, Daniel R. Soverow, Jonathan Meymandi, Sheba K.
spellingShingle	Forsyth, Colin J. Hernandez, Salvador Olmedo, Wilman Abuhamidah, Adieb Traina, Mahmoud I. Sanchez, Daniel R. Soverow, Jonathan Meymandi, Sheba K. Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
author_facet	Forsyth, Colin J. Hernandez, Salvador Olmedo, Wilman Abuhamidah, Adieb Traina, Mahmoud I. Sanchez, Daniel R. Soverow, Jonathan Meymandi, Sheba K.
author_sort	Forsyth, Colin J.
title	Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
title_short	Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
title_full	Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
title_fullStr	Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
title_full_unstemmed	Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
title_sort	safety profile of nifurtimox for treatment of chagas disease in the united states
description	We assessed the frequency and severity of adverse events (AEs) in 53 patients with Chagas disease treated with nifurtimox in a US clinic. There were 435 AEs, but 93.8% were mild. Moderate/severe AEs were associated with premature treatment cessation.
publisher	Oxford University Press
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036918/
_version_	1613661289077276672

Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States

Similar Items